- Home
- GCI vs ATXS Comparison
GCI vs ATXS Comparison
Compare GCI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- ATXS
- Stock Information
- Founded
- GCI 1997
- ATXS 2008
- Country
- GCI United States
- ATXS United States
- Employees
- GCI N/A
- ATXS N/A
- Industry
- GCI Newspapers/Magazines
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- ATXS Health Care
- Exchange
- GCI Nasdaq
- ATXS Nasdaq
- Market Cap
- GCI 621.7M
- ATXS 676.1M
- IPO Year
- GCI N/A
- ATXS 2015
- Fundamental
- Price
- GCI $4.55
- ATXS $12.50
- Analyst Decision
- GCI Buy
- ATXS Hold
- Analyst Count
- GCI 3
- ATXS 6
- Target Price
- GCI $5.70
- ATXS $24.33
- AVG Volume (30 Days)
- GCI 3.1M
- ATXS 936.9K
- Earning Date
- GCI 10-30-2025
- ATXS 11-12-2025
- Dividend Yield
- GCI N/A
- ATXS N/A
- EPS Growth
- GCI N/A
- ATXS N/A
- EPS
- GCI 0.59
- ATXS N/A
- Revenue
- GCI $2,338,505,000.00
- ATXS $706,000.00
- Revenue This Year
- GCI N/A
- ATXS N/A
- Revenue Next Year
- GCI N/A
- ATXS N/A
- P/E Ratio
- GCI $7.65
- ATXS N/A
- Revenue Growth
- GCI N/A
- ATXS N/A
- 52 Week Low
- GCI $2.55
- ATXS $3.56
- 52 Week High
- GCI $5.69
- ATXS $12.72
- Technical
- Relative Strength Index (RSI)
- GCI 49.42
- ATXS 67.29
- Support Level
- GCI $4.96
- ATXS $12.31
- Resistance Level
- GCI $5.29
- ATXS $12.62
- Average True Range (ATR)
- GCI 0.34
- ATXS 0.23
- MACD
- GCI -0.04
- ATXS -0.17
- Stochastic Oscillator
- GCI 44.02
- ATXS 72.73
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.